Guillain-Barré syndrome related to SARS-CoV-2 infection
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) led to the death of thousands of people around the world.1 Neurologic manifestations are not much specific apart from acute anosmia, and postinfectious manifestation data are missing.2 We described the cases of 2 patients exhibiting demyelinating form of Guillain-Barré syndrome (GBS) and summarized neurologic manifestations and investigations results in table 1.

A 43-year-old man presented with cough, asthenia, and myalgia in legs, followed by acute anosmia and ageusia with diarrhea the next day. Symptoms resolved spontaneously after 2 weeks. Twenty-one days after the beginning of respiratory symptoms, he presented with in a rapidly progressive manner paraesthesia, hypoesthesia, and distal weakness in the lower limbs. In the following 2 days, these symptoms extended to the midthigh and tip of the fingers associated with ataxia, and he was hospitalized at day 4 because a right peripheral facial palsy had occurred. His body temperature was 36.9°C and oxygen saturation was 99%. Neurologic examination disclosed decreased light touch from midthigh to feet and the tip of the fingers; decreased vibration sense in the lower limbs, symmetric weakness for dorsiflexion and extension of the toes (Medical Research Council [MRC] score = 3/5) and flexion of the thigh (MRC = 4/5); and areflexia in the forelimbs apart from the left biceps reflex.
Laboratory results at day 4 were unremarkable (normal blood cell count, negative C-reactive protein, negatives HIV, Lyme, and syphilis serologies). Antigangliosides antibodies were negatives. Nasopharyngeal swab test was positive for SARS-CoV-2 on reverse transcription-polymerase chain reaction (RT-PCR) assay. CT of the chest showed ground-glass opacities in 10–25% on both lungs (figure e-1, links.lww.com/NXI/A267). CSF results showed normal cell count (1 × 106/L), increased protein level (0.94 g/L), and negative SARS-CoV-2 on RT-PCR assay. MRI at day 7 showed multiple cranial neuritis (in nerves III, V, VI, VII, and VIII), radiculitis, and plexitis on both the brachial and lumbar plexus (figure e-2, links.lww.com/NXI/A267). Nerve conduction studies at day 9 showed 2 conduction blocks (>50%) in both peroneal nerves, decreased motor conduction velocities in both peroneal and tibial nerves approximately 30–37 m/s, a sural sparing pattern, abolition of the H-reflex, and slightly increased of F-wave latencies supporting demyelinating pattern (table e-1, links.lww.com/NXI/A267). The patient was diagnosed with GBS, and IV immunoglobulin infusions (IVIg) were started at day 5 (2 g/kg). He was rapidly discharged home with progressive improvement.
An obese 70-year-old woman presented with anosmia and ageusia, followed by diarrhea for 2 days. She complained of mild asthenia and myalgia without fever. All symptoms resolved excepted anosmia and ageusia. Nasopharyngeal swab test was positive for SARS-CoV-2 on RT-PCR assay. Seven days later, she presented with acute proximal tetraparesis and distal forelimb and perioral paraesthesia. She was hospitalized for dyspnea and loss of ambulation 3 days later and was rapidly transferred to an intensive care unit for noninvasive ventilation for acute respiratory failure with hypercapnia. She was discharged from the intensive care unit 9 days later, without requiring invasive mechanical ventilation. Neurologic examination disclosed proximal lower-limb weakness (MRC 2/5), distal weakness (MRC 4/5), and diffuse areflexia.
At admission, C-reactive protein was slightly increased at 22 mg/L. Antigangliosides antibodies were negative. CSF results showed subnormal cell count (6 × 106/L), increased protein level (1.06 g/L), and negative SARS-CoV-2 on RT-PCR assay. CT of the chest showed moderate ground-glass opacities in both lungs (figure e-1, links.lww.com/NXI/A267). Nerve conductions studies at day 7 showed a typical demyelinating pattern with a conduction block in the left median nerve, temporal dispersion, upper limb increased motor distal latencies, diffuse decreased motor and sensory conduction velocities lower than 38 m/s in 9 nerves of 10 tested (table e-1, links.lww.com/NXI/A267), and neurogenic pattern on EMG. IVIg (2 g/kg) were started at day 4 after the onset of the first neurologic symptoms. Left peripheral facial palsy occurred in a delayed manner at day 9. Her clinical condition improved slowly with physiotherapy, needing a transfer in a rehabilitation center.
We reported here 2 cases of GBS related to SARS-CoV-2 infection with neurologic improvement on IVIg, adding to few cases of GBS, one case of Miller Fisher syndrome, and one case of polyneuritis cranialis already published.
The first case report described a patient with GBS whose symptoms began 7 days before COVID-19, which asks the question of parainfectious profile or coincidence.3 However, previous reports and our cases suggest that GBS associated with SARS-CoV-2 infection could start between 5 and 21 days after the SARS-CoV-2 clinical symptoms.4 It could follow a postinfectious profile as reported on Middle East respiratory syndrome coronavirus infection in 4 patients with Bickerstaff's encephalitis overlapping with GBS.5
Thus, our cases add to several other reported cases and strengthen the view that GBS occurs with COVID-19.
Appendix Authors



References
1.
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
2.
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol Epub 2020 April 10.
3.
Zhao H, Shen D, Zhou H, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383–384.
4.
Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Engl J Med Epub 2020 Apr 17.
5.
Kim JE, Heo JH, Kim HO, et al. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol 2017;13:227–233.
Information & Authors
Information
Published In
Neurology® Neuroimmunology & Neuroinflammation
Volume 7 • Number 5 • September 3, 2020
PubMed: 32461235
Copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Publication History
Received: April 29, 2020
Accepted: May 6, 2020
Published online: May 27, 2020
Published in print: September 3, 2020
Disclosure
K. Bigaut, M. Mallaret, S. Baloglu, B. Nemoz, P. Morand, F. Baicry, A. Godon, P. Voulleminot, L. Kremer, J.-B. Chanson, and J. de Seze report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.
Study Funding
No targeted funding reported.
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Pathophysiological, immunological, and inflammatory features of long COVID, Frontiers in Immunology, 15, (2024).https://doi.org/10.3389/fimmu.2024.1341600
- Explore genetic susceptibility association between viral infections and Guillain-Barré syndrome risk using two-sample Mendelian randomization, Journal of Translational Medicine, 22, 1, (2024).https://doi.org/10.1186/s12967-024-05704-8
- A nationwide Guillain–Barré syndrome epidemiological study in Spain during the COVID ‐19 years , European Journal of Neurology, 31, 12, (2024).https://doi.org/10.1111/ene.16439
- Imaging and neuropathological findings in patients with Post COVID-19 Neurological Syndrome—A review, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1136348
- Bradycardia unresponded to atropin testing was successfully treated with therapeutic plasma exchange in a patient with severe COVID-19 complicated by Guillain-Barré syndrome: A case report, Frontiers in Cardiovascular Medicine, 9, (2023).https://doi.org/10.3389/fcvm.2022.1035896
- Microorganisms in Pathogenesis and Management of Guillain–Barré Syndrome (GBS), Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases, (177-194), (2023).https://doi.org/10.1007/978-981-19-4800-8_9
- COVID-19-associated Guillain–Barre syndrome: A case series with review of literature, Indian Journal of Health Sciences and Biomedical Research (KLEU), 15, 2, (168), (2022).https://doi.org/10.4103/kleuhsj.kleuhsj_407_21
- The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report, Journal of Personalized Medicine, 12, 11, (1822), (2022).https://doi.org/10.3390/jpm12111822
- A Systematic Review on Neurological Aspects of COVID-19: Exploring the Relationship Between COVID-19-Related Olfactory Dysfunction and Neuroinvasion, Frontiers in Neurology, 13, (2022).https://doi.org/10.3389/fneur.2022.887164
- Demographic, Clinical, and Investigational Characteristics of COVID-19- related Guillain-Barré Syndrome with Differences from Typical and Another Virus-related Guillain-Barré Syndrome, Infectious Disorders - Drug Targets, 22, 7, (2022).https://doi.org/10.2174/1871526522666220429134113
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.